Technavio, a US-based global technology research and advisory company, announced on Thursday that the global peptide therapeutics market size is expected to increase by USD17.85bn from 2024 to 2028.
The market size is predicted to increase at a CAGR of 10.03% during the forecast period.
Increasing prevalence of infectious diseases is driving market growth, with a trend towards collaborations for R and D, but complexities in manufacturing, storage conditions, distribution policies, and high cost pose a challenge.
The main market players include Almac Group Ltd., AmbioPharm Inc., Amgen Inc., AstraZeneca Plc, Bachem AG, Bristol Myers Squibb Co., Corden Pharma International GmbH, Eli Lilly and Co., Ever Pharma, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Ipsen Pharma, Lonza Group Ltd., Novartis AG, Novo Nordisk AS, PeptiDream Inc., Pfizer Inc., PolyPeptide Group, Sanofi SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd. and Worg pharma.
TC BioPharm plans Proof of Concept preclinical studies of TCB 008 for treatment of monkey pox
LakeShore Biopharma names new chief executive officer
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
RedHill Biopharma launches Talicia in UAE for H. pylori treatment
RedHill Biopharma reports promising results for opaganib in obesity and diabetes studies
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI
Technavio predicts increase in global peptide therapeutics market size